Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Subject to clinician approval
Yes, with outcomes consistent with general adult data
Government of Canada, The Daily The prevalence of overweight and obesity is on the rise in Canada: New results from the Canadian Health Measures Survey, 2022 to 2024. Accessed: Nov
on April 21, 2026 CMS declined to implement it in Part D for 2027 and extended the GLP-1 Bridge through Dec 31, 2027 instead
Preclinical signals regarding potential effects on thyroid C-cells (observed with GLP-1 agonists as a class), as well as theoretical questions about bone metabolism and cardiovascular function, are being monitored in ongoing trials
US$ 27.25
US$ 20.54
US$ 23.40
US$ 23.37
